Literature DB >> 23630544

Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications.

James S Testa1, Ramila Philip.   

Abstract

Prophylactic and therapeutic vaccines against viral infections have advanced in recent years from attenuated live vaccines to subunit-based vaccines. An ideal prophylactic vaccine should mimic the natural immunity induced by an infection, in that it should generate long-lasting adaptive immunity. To complement subunit vaccines, which primarily target an antibody response, different methodologies are being investigated to develop vaccines capable of driving cellular immunity. T-cell epitope discovery is central to this concept. In this review, the significance of T-cell epitope-based vaccines for prophylactic and therapeutic applications is discussed. Additionally, methodologies for the discovery of T-cell epitopes, as well as recent developments in the clinical testing of these vaccines for various viral infections, are explained.

Entities:  

Keywords:  MHC class I; cellular immunity; cytotoxic T cells; epitopes; humoral immunity; immunoproteomics; mass spectrometry; vaccine

Year:  2012        PMID: 23630544      PMCID: PMC3636528          DOI: 10.2217/fvl.12.108

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  108 in total

1.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

2.  Hidden epitopes emerge in secondary influenza virus-specific CD8+ T cell responses.

Authors:  Paul G Thomas; Scott A Brown; Rachael Keating; Wen Yue; Melissa Y Morris; Jenny So; Richard J Webby; Peter C Doherty
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 3.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

Review 4.  Antigen processing and presentation by the class I major histocompatibility complex.

Authors:  I A York; K L Rock
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 5.  Epitope discovery and their use in peptide based vaccines.

Authors:  Nadine L Dudek; Patrick Perlmutter; Marie-Isabel Aguilar; Nathan P Croft; Anthony W Purcell
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

6.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

7.  A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains.

Authors:  C A van Els; C A Herberts; E van der Heeft; M C Poelen; J A van Gaans-van den Brink; A van der Kooi; P Hoogerhout; G Jan ten Hove; H D Meiring; A P de Jong
Journal:  Eur J Immunol       Date:  2000-04       Impact factor: 5.532

8.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Authors:  A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

9.  MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response.

Authors:  James S Testa; Vivekananda Shetty; Julie Hafner; Zacharie Nickens; Shivali Kamal; Gomathinayagam Sinnathamby; Ramila Philip
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  HLA class I supertypes: a revised and updated classification.

Authors:  John Sidney; Bjoern Peters; Nicole Frahm; Christian Brander; Alessandro Sette
Journal:  BMC Immunol       Date:  2008-01-22       Impact factor: 3.615

View more
  11 in total

1.  Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.

Authors:  Joseph D Comber; Aykan Karabudak; Xiaofang Huang; Paolo A Piazza; Ernesto T A Marques; Ramila Philip
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  A candidate multi-epitope vaccine against SARS-CoV-2.

Authors:  Tamalika Kar; Utkarsh Narsaria; Srijita Basak; Debashrito Deb; Filippo Castiglione; David M Mueller; Anurag P Srivastava
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

3.  In silico epitope-based vaccine design against influenza a neuraminidase protein: Computational analysis established on B- and T-cell epitope predictions.

Authors:  Shaia Almalki; Saba Beigh; Naseem Akhter; Read A Alharbi
Journal:  Saudi J Biol Sci       Date:  2022-04-21       Impact factor: 4.052

Review 4.  Targeting memory T cell metabolism to improve immunity.

Authors:  Mauro Corrado; Erika L Pearce
Journal:  J Clin Invest       Date:  2022-01-04       Impact factor: 14.808

5.  Epitope-Based Peptide Vaccine Design against Fructose Bisphosphate Aldolase of Candida glabrata: An Immunoinformatics Approach.

Authors:  Lina Mohamed Elamin Elhasan; Mohamed B Hassan; Reham M Elhassan; Fatima A Abdelrhman; Essam A Salih; Asma Ibrahim H; Amna A Mohamed; Hozaifa S Osman; Marwa Saad M Khalil; Athar A Alsafi; Abeer Babiker Idris; Mohamed A Hassan
Journal:  J Immunol Res       Date:  2021-05-04       Impact factor: 4.818

6.  Epitope Identification and Designing a Potent Multi-epitope Vaccine Construct against SARS-CoV-2 Including the Emerging Variants.

Authors:  Sivasubramanian Srinivasan; Gracy Fathima Selvaraj; Vidya Gopalan; Padmapriya Padmanabhan; Kiruba Ramesh; Karthikeyan Govindan; Aswathi Chandran; Prabu Dhandapani; Kaveri Krishnasamy; Satish Srinivas Kitambi
Journal:  J Glob Infect Dis       Date:  2022-02-17

Review 7.  Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances.

Authors:  Jiahui Zhang; Jingyi Fan; Mariusz Skwarczynski; Rachel J Stephenson; Istvan Toth; Waleed M Hussein
Journal:  Int J Nanomedicine       Date:  2022-02-25

Review 8.  Peptide Vaccine: Progress and Challenges.

Authors:  Weidang Li; Medha D Joshi; Smita Singhania; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Vaccines (Basel)       Date:  2014-07-02

9.  A computational assay to design an epitope-based Peptide vaccine against saint louis encephalitis virus.

Authors:  Md Anayet Hasan; Mehjabeen Hossain; Md Jibran Alam
Journal:  Bioinform Biol Insights       Date:  2013-11-24

10.  Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine.

Authors:  Babu Ramanathan; Chit Laa Poh; Kristin Kirk; William John Hannan McBride; John Aaskov; Lara Grollo
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.